Today's Top 5
5. Lifastuzumab vedotin for NSCLC and Ovarian Cancer
Phase 1a study: lifastuzumab vedotin in NSCLC and ovarian cancer. https://t.co/5ktbDEZM6K pic.twitter.com/fuNTv4aijc
— ClinicalCancer Research (@CCR_AACR) January 23, 2020
4. Treat Until MRD Negativity
Other ideas would to potentially only treat till MRD negativity❌. Use that as a dynamic marker once utility/timing has been studied more. Put that into our current clinical algorithms of identifying who we give chemo to. #LiquidBiopsies #ctDNAinsights #OncoAlert #CRCSM pic.twitter.com/6rPLc6lUdr
— Pashtoon Kasi MD, MS (@pashtoonkasi) January 23, 2020
3. T-Cell Depletion in Multiple Myeloma Transplantation
New #JITC article: Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study https://t.co/lSQNzWh1cZ pic.twitter.com/9TWWZWQb2r
— Journal for ImmunoTherapy of Cancer (@jitcancer) January 20, 2020
2. Improving Communication with Patients
How can oncology teams better communicate with their patients about their care? How can we improve access to clinical trials? Listen to our interview withMary Elizabeth Williams, one of the first combination IO patients: https://t.co/SNRrmyR6Tn
— ACCC(@ACCCBuzz) January 24, 2020
1. FDA Approves First Treatment for EpithelioidSarcoma
ICYMI - @US_FDA approves first treatment option specifically for patients with #epithelioid #sarcoma, a rare soft tissue cancer.
— Memorial Sloan Kettering Cancer Center (@sloan_kettering) January 24, 2020
"This opens up an entirely new field in cancer," lead investigator, Dr. Mrinal Gounder. https://t.co/nhtoqiNNdj